<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983966</url>
  </required_header>
  <id_info>
    <org_study_id>3-2021-0214</org_study_id>
    <nct_id>NCT04983966</nct_id>
  </id_info>
  <brief_title>Comparison of Postoperative QoR-15 Scores Between Desflurane and Remimazolam in Lumbar Fusion Surgery</brief_title>
  <official_title>Comparison of Quality of Recovery (QoR)-15 Scores According to the Anesthetics (Desflurane vs. Remimazolam) in the Patients With Lumbar Fusion Surgery: a Prospective Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the quality of recovery (QoR)-15 scores according to&#xD;
      the use of maintenance anesthetics in the lumbar fusion surgery. Total intravenous anesthesia&#xD;
      (TIVA) have been known to help reducing risks of postoperative nausea/vomiting and malignant&#xD;
      hyperthermia. However, it is still not enough to explain which is better between TIVA or&#xD;
      inhalation anesthesia. In particular, there is no study to investigate overall postoperative&#xD;
      functional recovery via QoR-15 in patients receiving TIVA with remimazolam. The hypothesis of&#xD;
      our study is that total intravenous anesthesia based on remimazolam will demonstrate better&#xD;
      quality of recovery compared with the anesthesia based on inhalation using desflurane.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference of QoR-15 scores</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>The difference of scores in the Quality of Recovery (QoR)-15 survey between desflurane group and remimazolam group. 0 (minimum), 150 (maximum): Higher scores means better.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Lumbar Fusion Surgery</condition>
  <arm_group>
    <arm_group_label>Desflurane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General anesthesia with volatile agent of desflurane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5-1.5 mg/kg/h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desï¬‚urane</intervention_name>
    <description>General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.&#xD;
Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5</description>
    <arm_group_label>Desflurane group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.&#xD;
Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5</description>
    <arm_group_label>Remimazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Adult patients who aged 20-70 years with ASA-PS 1-3, BMI &lt;30 undergoing lumbar fusion&#xD;
        surgery under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tolerance or hypersensitivity to benzodiazepine or propofol&#xD;
&#xD;
          -  Dependence or addiction to psychotropic drugs or alcohol&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  subjects who lack the ability to make decisions and susceptible to voluntary&#xD;
             participation decisions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myung Hwa Kim</last_name>
    <phone>82-2-2019-4601</phone>
    <email>KMH2050@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Hwa Kim</last_name>
      <phone>82-2-2019-4601</phone>
      <email>KMH2050@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Myoung Hwa Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

